Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)

Autor: Holch, J.W., Held, S., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Heintges, T., Kahl, C., Kullmann, F., Scheithauer, W., Moehler, M., von Einem, J.C., Michl, M., Heinemann, V.

Publikováno v: In Annals of Oncology January 2020 31(1):72-78

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

Autor: Holch, J.W., Ricard, I., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Heintges, T., Kahl, C., Kullmann, F., Scheithauer, W., Moehler, M., Jelas, I., Modest, D.P., Westphalen, C.B., von Einem, J.C., Michl, M., Heinemann, V.

Publikováno v: In European Journal of Cancer January 2019 106:115-125

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Autor: Stintzing, S., Miller-Phillips, L., Modest, D.P., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Scheithauer, W., Held, S., Moehler, M., Jagenburg, A., Kirchner, T., Jung, A., Heinemann, V.

Publikováno v: In European Journal of Cancer July 2017 79:50-60

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306

Autor: Stintzing, S., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Jäger, E., Heintges, T., Stoll, C., Giessen, C., Modest, D.P., Neumann, J., Jung, A., Kirchner, T., Scheithauer, W., Heinemann, V. ^*

Publikováno v: In Annals of Oncology July 2012 23(7):1693-1699

Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.

Autor: Hofmann FO; Department of Radiology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany. Felix.Hofmann@med.uni-muenchen.de.; Department of General, Visceral and Transplantation Surgery, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany. Felix.Hofmann@med.uni-muenchen.de.; German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Centre (DKFZ), Heidelberg, Germany. Felix.Hofmann@med.uni-muenchen.de., Heinemann V; German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Centre (DKFZ), Heidelberg, Germany.; Department of Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany., D'Anastasi M; Department of Radiology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.; Mater Dei Hospital, University of Malta, Triq tal-Qroqq, Msida, MSD2090, Malta., Gesenhues AB; Department of Radiology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany., Hesse N; Department of Radiology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany., von Weikersthal LF; Klinikum St. Marien Amberg, Amberg, Germany., Decker T; Onkologische Praxis, Ravensburg, Germany., Kiani A; Department of Medicine IV, Klinikum Bayreuth GmbH, Bayreuth, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany., Moehler M; Department of Internal Medicine I, University Medical Center Mainz, Mainz, Germany., Kaiser F; VK&K Studien GbR, Landshut, Germany., Heintges T; Rheinlandklinikum Neuss, Lukaskrankenhaus, Neuss, Germany., Kahl C; Department of Hematology, Oncology and Palliative Care, Klinikum Magdeburg gGmbH, Magdeburg, Germany., Kullmann F; Department of Internal Medicine I, Hospital Weiden, Weiden, Germany., Scheithauer W; Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Link H; Department of Medicine I, Westpfalz-Klinikum GmbH, Kaiserslautern, Germany., Modest DP; Medical Department of Hematology, Oncology and Cancer Immunology (CCM), Charité-Universitätsmedizin Berlin, Berlin, Germany., Stintzing S; Medical Department of Hematology, Oncology and Cancer Immunology (CCM), Charité-Universitätsmedizin Berlin, Berlin, Germany., Holch JW; German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Centre (DKFZ), Heidelberg, Germany.; Department of Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.

Publikováno v: European radiology [Eur Radiol] 2023 Feb; Vol. 33 (2), pp. 1174-1184. Date of Electronic Publication: 2022 Aug 17.